Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Giunti

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Diabetes|April 6, 2001
Autoantibody response to CD38 in Caucasian patients with type 1 and type 2 diabetes: immunological and genetic characterizationR Mallone, E Ortolan, G Baj, et al.
Diabetologia|July 3, 2008
The HMG-CoA reductase inhibitor rosuvastatin and the angiotensin receptor antagonist candesartan attenuate atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes via effects on advanced glycation, oxidative stress and inflammationA C Calkin, S Giunti, K J Sheehy, et al.
Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology|March 3, 2001
[Epidemiologic analysis of the incidence of new diabetic patients on dialysis as a basis for a clinical study]M Ferro, G B Piccoli, M Burdese, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 10, 2004
Lack of evidence for the 1484insG variant at the 3'-UTR of the protein tyrosine phosphatase 1B (PTP1B) gene as a genetic determinant of diabetic nephropathy development in type 1 diabetic patientsS De Cosmo, A Marucci, E Ciociola, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Diabetes|April 6, 2001
Autoantibody response to CD38 in Caucasian patients with type 1 and type 2 diabetes: immunological and genetic characterizationR Mallone, E Ortolan, G Baj, et al.
Diabetologia|July 3, 2008
The HMG-CoA reductase inhibitor rosuvastatin and the angiotensin receptor antagonist candesartan attenuate atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes via effects on advanced glycation, oxidative stress and inflammationA C Calkin, S Giunti, K J Sheehy, et al.
Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology|March 3, 2001
[Epidemiologic analysis of the incidence of new diabetic patients on dialysis as a basis for a clinical study]M Ferro, G B Piccoli, M Burdese, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 10, 2004
Lack of evidence for the 1484insG variant at the 3'-UTR of the protein tyrosine phosphatase 1B (PTP1B) gene as a genetic determinant of diabetic nephropathy development in type 1 diabetic patientsS De Cosmo, A Marucci, E Ciociola, et al.
Pageof 2